FDA Rejects Summit Therapeutics' Ivonescimab in EGFR-Mutant Lung Cancer

SentiSense · Published · Updated

The FDA issued a complete response letter for Summit Therapeutics' ivonescimab, a PD-1 x VEGF bispecific antibody, in previously treated EGFR-mutated non-small cell lung cancer, Summit announced on November 15. The agency said a progression-free survival benefit without a statistically significant overall survival improvement does not support approval. Jefferies reiterated a Buy rating and $30.00 price target, citing HARMONi-3 data around year-end 2026 as the next catalyst.

The FDA has issued a complete response letter for Summit Therapeutics' (SMMT) biologics license application for ivonescimab, Summit announced on Sunday, November 15. The application covered ivonescimab plus platinum-containing chemotherapy in locally advanced or metastatic non-small cell lung cancer in patients previously treated with an EGFR tyrosine kinase inhibitor. Fierce Pharma's headline framed the decision as derailing the US arrival of the PD-1 x VEGF class.

The reason was survival data. Summit said the FDA determined that substantial evidence of effectiveness was not established without a statistically significant overall survival improvement, and that a progression-free survival benefit alone did not support a positive benefit-risk profile. The HARMONi trial met its progression-free survival endpoint, but Summit said overall survival showed a positive trend without reaching statistical significance in the primary analysis. In a post-hoc analysis, the company reported a hazard ratio of 0.76 across the full population and both the Asian and western subgroups. No PD-1 x VEGF bispecific antibody is currently approved in the US.

Jefferies reiterated a Buy rating and $30.00 price target after the news, according to Investing.com. The firm said the complete response letter was the investor base case and that it sees limited downside. Stifel lowered its price target to $37 from $38 and kept a Buy rating, and Citizens reaffirmed Market Outperform with a $40 target, the same report said. Summit shares closed at $14.15 before the announcement, against a 52-week high of $29.23. Trading in response to the letter had not yet occurred, because Monday is the first session after the news.

Chairman and Co-Chief Executive Officer Robert Duggan said in the company statement that nothing changes in Summit's belief in the drug, pointing to five positive Phase III studies between Summit and its partner Akeso, which invented ivonescimab and holds the China rights. Summit did not describe a resubmission, a new trial, or a meeting with the FDA. Jefferies pointed to HARMONi-3 squamous progression-free survival data around year-end 2026 as the next key event.

Related Stocks

Powered by SentiSense - Intelligent Market Analysis